Malignant carotid body paraganglioma

Summary

Malignant carotid body paraganglioma (MONDO:0004650) is a disease. A subtype of central nervous system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignant carotid body paraganglioma
Mondo ID	MONDO:0004650
DOID	DOID:8731
ICD-10-CM	C75.4
NCIT	C3574
SNOMED CT	447883002
UMLS	C0153656
MedGen	56318
GARD	0024080
Is cancer (heuristic)	no

Also known as: carotid body paraganglioma, malignant · malignant carotid body paraganglioma · malignant carotid body tumor (morphologic abnormality) · malignant carotid body tumour · malignant carotid body tumour (morphologic abnormality) · malignant tumour of carotid body · malignant tumour of the carotid body

Disease family

This is a subtype of central nervous system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › malignant carotid body paraganglioma

Related subtypes (19): central nervous system primitive neuroectodermal neoplasm, brain cancer, central nervous system sarcoma, primary central nervous system lymphoma, central nervous system germinoma, central nervous system melanocytic neoplasm, central nervous system endodermal sinus tumor, spinal cord cancer, malignant adrenal gland pheochromocytoma, malignant jugulotympanic paraganglioma, pheochromocytoma/paraganglioma syndrome 2, pheochromocytoma/paraganglioma syndrome 5, central nervous system Ewing sarcoma/peripheral primitive neuroectodermal tumor, choriocarcinoma of the central nervous system, mixed germ cell tumor of central nervous system, embryonal carcinoma of the central nervous system, malignant tumor of meninges, malignant central nervous system mesenchymal, non-meningothelial neoplasm, malignant glioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.